摘要:
Objective To compare the outcomes between haploidentical donor hematopoietic stem cell transplantation (haplo-HSCT) and matched-sibling donor transplantation (MSD-HSCT) for paroxysmal nocturnal hemoglobinuria (PNH).Methods The clinical data of 40 PNH patients received HSCT (haplo-HSCT=25,MSD-HSCT =15) from July 2007 to May 2018 were analyzed retrospectively to compare the outcomes between haplo-HSCT and MSD-HSCT groups.Results There were no differences in terms of gender,age,patients of PNH-AA and median time from diagnosis to transplantation between the 2 groups (P > 0.05).The median values of absolute mononuclear cell counts and CD34+ cells infused were 10.74(4.80-22.86) × 108/kg and 12.19 (5.14-17.25)× 108/kg (P=0.866),3.57 (0.68-7.80) × 106/kg and 4.00(3.02-8.42) × 106/kg (P=0.151) respectively,in haplo-HSCT and MSD-HSCT groups.All patients attained complete engraftment,no patient occurred graft failure.The median durations for myeloid and platelet engraftment were 12 (range,9-26) and 11 (range,7-15) days (P =0.065),19(range,1 1-75) and 13 (range,11-25) days (P =0.027) respectively,in haplo-HSCT and MSD-HSCT groups.During a median follow-up of 26 (4-65) months in haplo-HSCT and 36 (4-132) months in MSD-HSCT groups (P =0.294),the incidences of grade Ⅰ-Ⅳ acute graft-versus-host disease (aGVHD)were 32.0% and 20.0% (P=0.343),grade Ⅱ-Ⅳ aGVHD were 16.0%,13.3% (P=0.759),chronic GVHD were 30.7% and 24.6% (P=0.418),moderate-severe chronic GVHD were 12.7% and 7.1% (P=0.522) respectively,in haplo-HSCT and MSD-HSCT groups.The incidences of infection were 32.0%(8/25) and 26.7% (4/15) (P=1.000) respectively,in haplo-HSCT and MSD-HSCT groups.No patients occurred early death and relapse.Three-year estimated overall survival (OS) were (86.5 ± 7.3) % and (93.3 ±6.4)% (P=0.520),GVHD-free and failure-free survival (GFFS) were (78.3±8.6)% and (92.9±6.9) % (P=0.250) respectively,in haplo-HSCT and MSD-HSCT groups.Conclusion The preliminary results indicated that haplo-HSCT was a feasible choice for PNH with favorable outcomes,haplo-HSCT and MSD-HSCT produced similar therapeutic efficacy.%目的 比较单倍型与同胞全相合移植治疗阵发性睡眠性血红蛋白尿症(PNH)的疗效及安全性.方法 总结2007年7月至2018年5月40例(单倍型移植25例,同胞全相合移植15例)接受异基因造血干细胞移植的PNH患者临床资料,对两组疗效及安全性进行比较.结果 单倍型移植组及同胞全相合移植组患者性别、年龄、PNH-再生障碍性贫血(AA)患者比例、诊断至移植时间差异均无统计学意义(P> 0.05).单倍型移植组及同胞全相合组回输单个核细胞数(MNC)分别为10.74(4.80~22.86)×108/kg与12.19(5.14~17.25)×108/kg (P=0.866),回输CD34+细胞数分别为3.57(0.68 ~ 7.80)×106/kg与4.00(3.02~ 8.42)×106/kg(P=0.151).所有患者均成功植入,单倍型移植组及同胞全相合移植组粒细胞植入时间分别为12(9~26)d与11(7~15)d(P=0.065),血小板植入时间分别为19(11~ 75)d与13(11 ~ 25)d (P=0.027).单倍型移植组与同胞全相合移植组Ⅰ~Ⅳ度急性GVHD发生率分别32.0%、20.0% (P=0.343),Ⅱ~Ⅳ度急性GVHD发生率分别为16.0%、13.3%(P=0.759).慢性GVHD发生率分别为30.7%、24.6% (P=0.418),中重度慢性GVHD发生率分别为12.7%、7.1%(P=0.522).移植过程中单倍型移植组与同胞全相合移植组感染发生率分别为32.0% (8/25)、26.7%(4/15)(P=1.000),未发生早期死亡.单倍型移植组及同胞全相合移植组预期3年总生存(OS)率分别为(86.5±7.3)%、(93.3±6.4)%(P=0.520),无移植物抗宿主病无失败生存(GFFS)率分别为(78.3± 8.6)%、(92.9±6.9)%(P=0.250).在随访期内两组患者均无复发.结论 单倍型移植用于治疗PNH具有与同胞全相合移植相似的疗效及安全性,在无全相合供者情况下可作为PNH患者有价值的治疗手段.